Research Article

Prognostic Implication of a Cuproptosis-Related miRNA Signature in Hepatocellular Carcinoma

Ze Jin, Mengmeng Wang, Yajun Meng, Di Chen, Yushuang Xu, Xin Jiang, and Zhifan Xiong

Department of Gastroenterology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Correspondence should be addressed to Zhifan Xiong; xionghifan@126.com

Received 29 May 2022; Revised 22 August 2022; Accepted 23 August 2022; Published 13 September 2022

1. Introduction

Liver cancer is the sixth most common cancer with almost 906,000 new cases in 2020, which ranks the third leading cause of cancer-related death worldwide [1]. Hepatocellular carcinoma (HCC) is the most prevalent histologic type, accounting for ~90% of patients diagnosed with liver cancer [2]. Infection by hepatitis B and C viruses is the main risk factor for HCC, and nonalcoholic fatty liver disease (NAFLD) is becoming a growing cause of HCC in the United States [3, 4]. Although advancements have been made in treatment, most patients with HCC present with intermediate and advanced stages of the disease, and treatments are frequently not curative [5, 6]. Prediction of clinical outcomes is being challenged because of the insidious symptoms and the high heterogeneity of HCC. Therefore, developing novel prognostic models for the personalized evaluation of cancer risk is urgently needed.

A recent study published in Science found that copper could directly bind to lipoylated mitochondrial enzymes, resulting in proteotoxic stress and destabilization of iron-sulfur (Fe-S) cluster proteins, which leads to cell death [7]. Copper toxicity induces a unique type of cell death distinct from regulated cell death (RCD) (e.g., apoptosis, ferroptosis [8], pyroptosis, and necroptosis [9]). Tsvetkov et al. termed this previously uncharacterized cell death “cuproptosis” [11] and identified several genes that related to copper-induced cell killing. For example, FDX1 encodes...
a small iron-sulfur protein acting as a mitochondrial reductase and is a direct target of elesclomol [11]. High-level copper concentrations have been detailed in the tumors or serum of patients with cancers, including lung [12, 13], breast [14], gastrointestinal [15], oral [16], thyroid [17], gall bladder [18], and prostate [19] cancers. Copper is crucial for regulating the activity of the autophagic kinases ULK1/2 to promote tumor development in lung cancer [20]. Gunjan et al. reported a case of neurological Wilson’s disease developing decompensated cirrhosis and HCC due to copper accumulation [21]. Additionally, copper chelators and ionophores have been suggested as anti-tumorigenic drugs [22]. Cui et al. reported that disulfiram reacts with Cu to form the Cu complex, which is the active agent that induces apoptosis in human melanoma cells [23]. Cui et al. demonstrated that copper-depleting nanoparticle administration inhibits tumor growth and substantially improves survival in mouse models of triple-negative breast cancer [24]. In the liver, lacking functional ATP7B leads to copper overload, which affects lipid metabolism and cell cycle [25, 26]. The significance of cuproptosis in HCC prognosis and immune function has not been explored.

Most encoding protein RNAs are modulated by one or more miRNAs [27, 28]. MicroRNAs (miRNA) are important in posttranslational regulation of gene expression via binding to messenger RNA, whereas their dysfunction has been demonstrated to mark many diseases including HCC [29]. In this study, differentially expressed miRNAs targeting cuproptosis-related genes (CRGs) between tumor and matched normal tissues of HCC were identified. Using univariate Cox regression and least absolute shrinkage and selection operator (LASSO) penalty, a prognostic cuproptosis-related miRNA (CRM) signature was constructed. The independent prognostic role of the model was determined by applying multivariate Cox regression and its relationship with tumor-immune microenvironment was also investigated. Then, a nomogram comprising the cuproptosis-miRNA signature and clinical variables was also established. Finally, differentially expressed genes (DEGs) based on risk score and immune score were further identified, and functional analysis and immune-related analysis were conducted to explore the potential mechanism.

2. Materials and Methods

2.1. Data Collection. The expression data of RNA and related information of 374 patients with liver cancer were downloaded from the TCGA database. From the TCGA-LIHC cohort, 184 tumor samples were randomly selected to form a test set. miRNAs targeting CRGs were acquired from the TargetScanHuman database. The transcriptome expression data were normalized utilizing the “limma” package and obtained by the “TCGAbiolinks” package. The acquisition of all data was analyzed complying with TCGA and TargetScanHuman data access policies. Thirteen CRGs were found in the published literature [7] (Supplement Table 1).

2.2. Establishment of the Prognostic Cuproptosis-Related miRNA Signature. The differentially expressed CRMs (DE-CRMs) were analyzed by “edgeR” package. Heatmap and volcano plot was used to visualize DE-CRMs. The criteria for selecting DE-miRNAs were log2fold change (|log2FC|)>1 and false discovery rate (FDR)<0.05. Univariate Cox analysis was performed to screen the DE-CRMs with the prognostic value (p<0.05). LASSO analysis was employed for those DE-CRMs to minimize overfitting via “glmnet” package with 10-fold cross-validation [30]. Finally, 14 cuproptosis-related miRNA model and their coefficients were identified for further study. A risk score was calculated using the formula: risk score = \sum_{i=1}^{n} \beta_i \times \text{Exp} (\beta_i \times \text{expression level of each miRNA, Exp}) (\text{expression level of miRNA}).

The patients with HCC were separated into two risk subgroups following the median risk score. “Survminer” R package was used to perform survival analysis. By using “survival” and “timeROC” R packages, the area under the curve (AUC) gained from the time-dependent receiver operating characteristic (ROC) analysis was measured. Multivariate Cox regression was conducted to test whether the CRM signature was an independent prognostic factor. In addition, survival analysis based on the test set and clinical subgroups were performed to validate the robustness of this risk model.

2.3. Development of a Predictive Nomogram. To calculate the probability of 1-, 3-, and 5-year OS for patients with HCC, a novel nomogram was built through “rms” and “regplot” packages. Gender, age, pathological stage, N stage, M stage, and risk score were enrolled in this nomogram. Calibration curves were displayed to estimate the prognostic ability of this prediction model compared to actual survival rates.

2.4. GSEA, Immune Cell Infiltration Analysis, and Drug Sensitivity Analysis. To clarify the intrinsic mechanisms of the cuproptosis-related miRNAs, GSEA analysis was performed to compare the biological conditions of the two risk groups. We estimated the correlation of immune cells and related pathways in low- and high-risk patients by applying single-sample gene set enrichment analysis (ssGSEA) with “gsva” R package [31]. The analyses of TIMER, CIBERSORT, CIBERSORTABS, XCELL, QUANTISEQ, EPIC, and MCP counter were implemented to discover the association between immune infiltration and the risk model. In addition, we also explored the relationship between immune checkpoint genes [32] (Supplement Table 2) and the risk model to predict the potential response to immune checkpoint blockade (ICB) therapies.

2.5. Identification and Functional Enrichment Analysis of DEGs Based on Risk Score and Immune Score. Risk-related DEGs between the high-risk and low-risk groups in patients with HCC were identified using “edgeR” package. Immune scores derived from ESTIMATE represent the level of infiltration of immune cells in tumor tissues [33]. According to the immune scores, patients with HCC were
classified into two groups: high-immune group and low-immune group, and immune-related DEGs were obtained following the immune score. The common DEGs based on risk score and immune score were visualized by Venn diagram. “ggplot2,” “enrichplot,” and “clusterProfiler” R packages were used to perform gene ontology (GO), the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was also conducted for DEGs mentioned above.

2.6. Statistical Analysis. Statistical analyses were executed with R software (version 4.1.3). Chi-square test was applied to match the categorical variables between the high- and low-risk groups. Student’s t test was used to compare the continuous variables between the two groups. $P < 0.05$ was considered the cutoff criterion of statistical significance. Adjusted $P$ values were achieved by Benjamini and Hochberg (BH) correction.

3. Results

3.1. Identification of DE Cuproptosis-Related miRNAs. A flowchart of data collection and analyses is described in Figure 1. The gene expression of 374 HCC samples was downloaded from the TCGA database with clinicopathological characteristics (Table 1). miRNAs targeting CRGs were achieved from the TargetScanHuman database. A total of 134 cuproptosis-related miRNAs were differentially
expressed between tumor tissues and nontumor tissues. Among them, 117 miRNAs significantly were upregulated in the tumor tissues, whereas 17 miRNAs were downregulated (Figures 2(a) and 2(b)).

3.2. Construction of a Prognostic CRM Signature in TCGA Cohort. Nineteen of DE cuproptosis-related miRNAs (DE-CRMs) related to OS were identified by performing univariate Cox regression analysis (Figure 2(c)). To minimize potential overfitting, 19 of DE-CRMs were submitted to LASSO Cox regression analysis to build the prognostic signature. The LASSO coefficients of the 19 survival-related CRMs are illustrated in Figure 2(d). Fourteen miRNAs are included with the best performance of the prognostic model in Figure 2(e). Finally, 14 prognostic cuproptosis-related miRNAs stood out for the establishment of the prognostic model. The corresponding risk scores were computed for the TCGA datasets using multivariate Cox regression analysis (Figure 2(f)), according to the following formula: risk score = - (0.050 * expression level of miR-767-5p + 0.177 * expression level of miR-3171+0.174 * expression level of miR-3189-3p + 0.208 * expression level of miR-3620-3p + 0.224 * expression level of miR-3911+(-0.537) * expression level of miR-6764-5p + 0.187 * expression level of miR-4652-3p + 0.246 * expression level of miR-504-3p + 0.068 * expression level of miR-892a + 0.336 * expression level of miR-548aq-5p).

According to the median cutoff value, the patients were divided into a high-risk group (n = 182) and a low-risk group (n = 183). The distributions of the risk scores and survival status supported the classification of patients with HCC into two groups by the miRNA risk model (Figure 3(a)). The differential expression of 14 CRMs between high-risk group and low-risk group is shown in Figure 3(b). The Kaplan-Meier survival curves indicated that the risk stratification could represent the different survival status of patients with HCC. High-risk subgroup exhibited prominently poorer OS relative to the low-risk subgroup (Figure 3(c), p < 0.001). Analysis of a time-dependent ROC and AUC found that the prognostic ability of the miRNA model was 0.709 (1 year), 0.712 (3 years), and 0.729 (5 years), which revealed that this risk signature has an accurate predictive ability for the outcome of patients with HCC (Figure 3(d)).

3.3. Independent Prognostic Value of CRM Signature and Construction of a Novel Nomogram for HCC Prognosis. Univariate Cox regression analysis indicated that the risk score had important association with OS in TCGA cohorts (p < 0.01, hazard ratio [HR]=1.995, 95% confidence interval [CI]=1.253–3.176), as well as several clinicopathological parameters, including pathologic overall stage (p < 0.0001, HR=2.993, 95% CI=1.897–4.723), pathological M stage (p = 0.019, HR=3.991, 95% CI=1.251–12.733). No obvious relevance was caught between clinical parameters and OS of patients with HCC, such as gender, age, and pathologic N stage. Multivariate Cox regression analysis supported that risk score is an independent prognostic predictor (p < 0.05, HR=1.821, 95% CI=1.126–2.943), as shown in Figures 3(e) and 3(f).

A nomogram was established to serve as a dependable, efficient tool for the prediction of OS in HCC that integrated the miRNA risk signature with significant clinical variables, including age, gender, overall stage, N stage, and M stage. The nomogram could provide the accurate prediction of survival rate in patients with HCC, as shown by the calibration curves (Figure 3(h)). These results implied that the nomogram could act as a quantitative method for the prognosis of patients with HCC and had great significance in clinical practice.

3.4. Validation of the Robustness of the CRM Model. To verify the predictive ability of CRM signature, a risk score was calculated for each sample in the test set. The distributions of the risk scores and survival status in test set proved the robustness of this model for stratifying patients with different risk (Figure 4(a)). The expression of 14 CRMs between high- and low-risk subgroups in test set is shown in Figure 4(b). The result of survival analysis indicated the

| Characteristics | No. of patients | Median OS (year) |
|-----------------|-----------------|-----------------|
| Age (years)     |                 |                 |
| <60             | 172 (45.6%)     | 1.55            |
| ≥60             | 204 (54.1%)     | 1.73            |
| NA              | 1 (0.3%)        | —               |
| Gender          |                 |                 |
| Female          | 122 (32.4%)     | 1.73            |
| Male            | 255 (67.6%)     | 1.58            |
| Histologic grade|                 |                 |
| G1              | 55 (14.6%)      | 1.90            |
| G2              | 180 (47.8%)     | 1.59            |
| G3              | 124 (32.9%)     | 1.58            |
| G4              | 13 (3.4%)       | 1.55            |
| NA              | 5 (1.3%)        | —               |
| Pathological stage|                |                 |
| I               | 175 (46.4%)     | 1.75            |
| II              | 87 (23.1%)      | 1.56            |
| III             | 86 (22.8%)      | 1.14            |
| IV              | 5 (1.3%)        | 0.61            |
| NA              | 24 (6.4%)       | —               |
| T               |                 |                 |
| T1              | 185 (49.1%)     | 1.75            |
| T2              | 95 (25.2%)      | 1.65            |
| T3              | 81 (21.5%)      | 1.12            |
| T4              | 13 (3.4%)       | 1.39            |
| NA              | 3 (0.8%)        | —               |
| N               |                 |                 |
| N0              | 257 (68.2%)     | 1.63            |
| N1-2            | 4 (1.1%)        | 1.79            |
| NA              | 116 (30.7%)     | —               |
| M               |                 |                 |
| M0              | 272 (72.1%)     | 1.62            |
| M1              | 4 (1.1%)        | 1.07            |
| NA              | 101 (26.8%)     | —               |

T: tumor; N: node; M: metastasis; OS: overall survival; NA: not available.

Table 1: Clinicopathological parameters of patients with HCC.
**Figure 2:** Construction of prognostic CRM signature in TCGA cohort. Heatmap (a) and a volcano plot (b) of the DE-CRMs in the TCGA cohort; the (c) forest plot of the univariate Cox regression analysis with DE-CRMs; (d) LASSO coefficient profiles of the 19 survival-related CRMs; (e) construction of the cuproptosis-related miRNA signatures by LASSO Cox analysis. The optimal parameter (λ) was selected as the first black dotted line indicated; (f) forest plot of the multivariate Cox regression analysis with 14 CRMs.

**Figure 3:** Continued.
Figure 3: Continued.
Figure 3: Characteristics of the risk score and a nomogram predicting OS for HCC patients in TCGA cohort. (a) The distributions of the risk scores and survival status in TCGA cohort; (b) the expression of 14 CRMs in two risk groups; (c) Kaplan-Meier curves of the miRNA signature in TCGA cohort; (d) the ROC analysis to estimate the predictive efficiency; forest plots of the (e) univariate and (f) multivariate Cox regression analyses in TCGA cohort; (g) the nomogram was constructed based on prognostic signature and clinical variables; (h) the calibration curve for evaluating the accuracy of the nomogram model.

Figure 4: Continued.
significant differences of prognosis in two risk groups of the
test set \((p < 0.001)\) (Figure 4(c)). Analysis of a time-dependent
ROC and AUC assessed the predictive accuracy of the miRNA
model in test set: 0.753 (−1 year), 0.772 (−3 years), and 0.765
(−5 years) (Figure 4(d)). Stratified prognostic analyses were
performed based on patient clinical characteristics, including
age, histologic grade, overall stage, and T stage (Figure 4(e)).
The results showed that cuproptosis-related miRNA signature
could distinguish the prognosis of patients at high and low
risks in different subgroups.

3.5. GSEA, Immune Cell Infiltration Analysis, and Drug
Sensitivity Analysis. The result of GSEA revealed that the
high-risk subtype enriched in several pathways related to
infection and inflammation, which implied that the
cuproptosis-related miRNAs might have regulative effects
on the activity of inflammation in HCC. Interestingly,
signaling pathways were enriched in the high-risk group:
NOD-like receptor signaling pathway and Ras signaling
pathway, which has been widely studied in association with
cancer (Figure 5). To apprehend the implication of miRNA
risk status and tumor microenvironment, the infiltration
levels of immune cells between high-risk group and low-risk
group in HCC were quantified. The heatmap depicted the
distinction of immune cell infiltration status in two different
risk groups (Figure 6(a)). The infiltration of 16 immune cells
and 13 immune-related functions in HCC samples was
analyzed with “ssGESA.” Correlations of the ratio of infil-
trating immune cells and related functions are shown in
Figures 6(b) and 6(c). CD8+ T cells were positively corre-
lated with tumor-infiltrating lymphocytes (TIL), as for
immune function, a significantly positive correlation was
observed between T-cell coinhibition and check point. To
further investigate the effect of immune checkpoint blockade
(ICB) therapies, the association between the expression level
of immune checkpoint genes (ICGs) and the risk score was
also analyzed. Several ICGs were differentially expressed
between two risk groups. It is noteworthy that TNFSF9,
TNFRSF4, LGALS9, CTLA4, and CD276 were highly
Figure 5: GSEA analysis of TCGA-LIHC.

Figure 6: Continued.
expressed in the high-risk group, which demonstrated potential effectiveness of ICB therapy (Figure 6(d)). These data suggest that the signature can predict the response to clinical treatment and may differentiate HCC patients who benefit from treatment.

3.6. Identification and Functional Analysis of DEGs Based on Risk Score and Immune Score. Given the important association between immune status and risk score mentioned above, intersected DEGs were also identified and further conducted the functional analysis. A total of 1335 DEGs...
were identified based on the risk score in patients with HCC, including 988 upregulated genes and 347 down-
regulated genes (|log2FC| > 1 and FDR < 0.05). Simulta-
neously, 2023 DEGs were obtained from the immune 
subgroups. Finally, 581 DEGs both in the risk group and 
immune group were identified (Figure 7(a)). Functional 
enrichment analyses were performed to characterize the 
biological functions and pathways of DEGs. GO func-
tional analysis of the DEGs revealed that they were 
enriched in biological processes including regulation of 
hormone secretion, signal release, and digestion, and 
involved in the component of the synaptic membrane. 
DEGs were also strongly linked to receptor ligand activity 
and signaling receptor activator activity (Figure 7(b)). 
Aberrant signaling processes induce a variety of cancers, 
and the enrichment in signaling activities uncovered the 
clinical significance of DEGs. KEGG analysis showed that 
DEGs were active in neuroactive ligand-receptor inter-
action, chemical carcinogenesis-receptor activation, and 
calcium signaling pathway (Figure 7(c)). The results indi-
cated that these DEGs might be thought important to 
HCC progression.

4. Discussion

HCC is one of the deadliest malignant tumors with worse 
survival rate and high-level heterogeneity. The pathological 
evaluation and AJCC TNM stage remain the major diag-
nostic and prognostic methods for patients with HCC, which 
are not accurate and sensitive enough. Patients with HCC 
with the same pathological stage have different treatment 
effectiveness and clinical outcomes. An accurate prediction 
of prognosis improves the doctors’ ability to decide indi-
vidual treatment strategies by identifying the risk status of 
patients. Therefore, exploring novel molecular biomarkers is 
urgently needed for improving the prognosis and quality of 
life of patients.

Recently, a study by Tsvetkov et al. was published in 
Science and declared a novel form of copper-induced cell 
death termed cuproptosis [7], which has drawn much at-
tention. Cell death has gained increasing prominence in 
tumor research, including apoptosis [34], ferroptosis [8], 
pyroptosis [35], and necroptosis [36]. Moreover, ionophores 
for copper replenishment can induce cuproptosis. On the 
other approach for cancer, copper depletion could reduce
the activity of angiogenic factors to suppress blood vessel development, and copper chelation has been recommended for cancer treatment due to its role as an antiangiogenic factor [37]. These findings suggested that therapies targeting cuproptosis might be a potential strategy for cancer. However, the value of cuproptosis in cancer prognosis especially in HCC remains unclear. miRNA is a small ~20–24 nucleotides molecules acting as essential regulators in the development of cancer, which influences cell cycle, metastasis, metabolism, and cell death. miRNAs were frequently found dysregulated in human malignancies and were potential biomarkers for multiple cancers [38, 39]. Especially, prognostic miRNA signatures targeting CRGs have not yet been explored in HCC.

In this study, the expression of miRNAs targeting 13 CRGs in HCC tumor tissues was systematically investigated, and the findings revealed that 19 miRNAs had prognostic value in patients with HCC. Then, a prognostic signature with 14 miRNAs targeting CRGs was constructed, which was proven as an independent predictor by using multivariate Cox regression analysis. Verification by sampling and stratified prognostic analyses exhibited that the miRNA signature has good performance in the prediction of patients’ outcomes in HCC. A novel nomogram integrating the risk signature and clinical parameters to provide individualized predictions was also built. Agreeably, the nomogram accurately predicts the 1-, 3-, and 5-year survival rates for patients with HCC. Moreover, different immune infiltrating conditions of the two risk groups were identified to investigate the association between the risk signature and the immune microenvironment. The results demonstrated that risk stratification was associated with several kinds of immune cell infiltration. The immune cells mediated the antitumor immune responses, and dysregulated antitumor immunity was associated with tumorigenesis, progression, and invasion [40]. However, the high-risk subtype was characterized by a distinct infiltration landscape of immune cells compared with low-risk subtype (macrophage, B cells, T cells), speculating that poor prognosis may be explained by the unfavorable immune microenvironment and deficiency of immunomodulation. Finally, the DEGs considering both the risk score and immune score were identified. The results of GO and KEGG revealed that these DEGs were involved in signaling and chemical carcinogenesis-receptor activation that might promote HCC progression. According to the results of GSEA, several signaling pathways also stood out in the high-risk group. Given the importance of the signaling pathways in tumor progression and development, the remarkable significance of this model in discriminating the different risk status was suggested.

Most of the miRNAs in this signature have emerged in studies related to cancers. MiR-767-5p promoted tumor aggressiveness and could be sponged by LINC-PINT in thyroid cancer [41]. Elevated expression of miR-767-5p was found in melanoma tissues and it acted as tumor promotor in melanoma [42]. Upregulated miR-767-5p was associated with cell proliferation, migration, and invasion, revealing the oncogenic role of miR-767-5p in breast cancer [43]. MiR-5003-3p promoted metastasis by targeting epithelial-mesenchymal transition (EMT) regulators in breast cancer [44] and exhibited similar functions in activating tumor progression in gastric cancer [45]. Hu et al. identified miR-504 as a directly suppressive regulator of p53 [46]. MiR-504 regulates ribosomal biogenesis and supports cancer cell survival [47]. Studies demonstrated that MiR-3171 is abnormally increased in bladder cancer and HCC tissues [48, 49]. Overall, these literature indicated that the cuproptosis-related miRNA signature might correlate with HCC progression and revealed prospective targets for the treatment of HCC.

This study has several strengths. It is the first to construct a prognostic signature focused on the cuproptosis-related miRNAs in HCC, which performed well in the prediction of patients with HCC. Second, immune cell infiltration analysis revealed that the miRNA signature existed dysregulated immune functions and the expression profiles of ICGs in different risk groups might provide a therapeutic strategy related to immune checkpoint inhibitors for patients with HCC. A composite prognostic nomogram was also established, and the calibration curve results suggested that the prediction of our nomogram was accurate and reliable. Furthermore, the DEGs based on risk score and immune score were identified to delineate a distinct set of genes. Functional enrichment analysis showed that these DEGs were enriched in some pathways associated with tumor progression. Nevertheless, the limitations of this study incorporate an insufficient sample size and a lack of experimental validation. The profound mechanism of cuproptosis-related miRNAs in the role of immune microenvironment and tumor progression of HCC requires further assessment.

5. Conclusion

This study identified a reliable prognostic signature based on cuproptosis-related miRNAs. It acts as a reliable prognostic model, and a nomogram with high availability including the risk score signature was constructed. Our findings might favor personalized prediction and therapeutic strategies. More large-sample studies are demanded to verify the feasibility of the risk signature. The underlying mechanisms between the miRNA signature and the development of HCC warrant further investigation.

Data Availability

The datasets presented in this study can be found in online repositories. The names of the repository(repositories and accession number(s) can be found in the article.

Ethical Approval

The work described in this article is in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for involving data relating to humans.

Conflicts of Interest

The authors declare that there are no conflicts of interest.
Authors’ Contributions

Ze Jin was responsible for conception and design and wrote the original draft. Mengmeng Wang and Yanjun Meng visualized and investigated the study. Di Chen, Yushuang Xu, and Xin Jiang provided software. Zhifan Xiong reviewed and edited the manuscript. All authors gave final approval of the version to be published and agreed to be accountable for all aspects of the work.

Acknowledgments

This study was supported by the National Key Research and Development Program of China (2018YFC2002000).

Supplementary Materials

Supplement Table 1: Cuproptosis-related genes. Supplement Table 2: Immune-checkpoint-related genes. (Supplementary Materials)

References

[1] H. Sung, J. Ferlay, R. L. Siegel et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: A Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209–249, 2021.
[2] J. M. Llovet, R. K. Kelley, A. Villanueva et al., “Hepatocellular carcinoma. Nat Rev Dis Primers,” PubMed Article, vol. 7, no. 1, p. 7, 2021.
[3] J. D. Yang, P. Hainaut, G. J. Gores, A. Amadou, A. Plymoth, and L. R. Roberts, “A global view of hepatocellular carcinoma: trends, risk, prevention and management,” Nature Reviews Gastroenterology & Hepatology, vol. 16, no. 10, pp. 589–604, 2019.
[4] C. Estes, H. Razavi, R. Loomba, A. Younossi, and A. J. Sanyal, “Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease,” Hepatology, vol. 67, no. 1, pp. 123–133, 2018.
[5] J. M. Llovet, R. Montal, D. Sia, and R. S. Finn, “Molecular therapies and precision medicine for hepatocellular carcinoma,” Nature Reviews Clinical Oncology, vol. 15, no. 10, pp. 599–616, 2018.
[6] A. Huang, X. R. Yang, W. Y. Chung, A. R. Dennison, and J. Zhou, “Targeted therapy for hepatocellular carcinoma,” Signal Transduction and Targeted Therapy, vol. 5, no. 1, p. 146, 2020 Published 2020 Aug 11.
[7] P. Tsvetkov, S. Coy, B. Petrova et al., “Copper induces cell death by targeting lipoylated TCA cycle proteins,” Science, vol. 375, no. 6586, pp. 1254–1261, 2022.
[8] X. Jiang, B. R. Stockwell, and M. Conrad, “Ferroptosis: mechanisms, biology and role in disease,” Nature Reviews Molecular Cell Biology, vol. 22, no. 4, pp. 266–282, 2021.
[9] S. Bedoui, M. J. Heroold, and A. Strasser, “Emerging connectivity of programmed cell death pathways and its physiological implications,” Nature Reviews Molecular Cell Biology, vol. 21, no. 11, pp. 678–695, 2020.
[10] M. A. Kahlson and S. J. Dixon, “Copper-induced cell death,” Science, vol. 375, no. 6586, pp. 1231–1232, 2022.
[11] P. Tsvetkov, A. Detappe, K. Cai et al., “Mitochondrial metabolism promotes adaptation to proteotoxic stress [published correction appears in Nat Chem Biol. 2019 Jun 4;],” Nature Chemical Biology, vol. 15, no. 7, pp. 681–689, 2019.
[12] M. Diez, F. J. Cerdà, M. Arroyo, and J. L. Balibrea, “Use of the copper/zinc ratio in the diagnosis of lung cancer,” Cancer, vol. 63, no. 4, pp. 726–730, 1989.
[13] Y. Jin, C. Zhang, H. Xu et al., “Combined effects of serum trace metals and polymorphisms of CYP1A1 or GSTM1 on non-small cell lung cancer: a hospital based case-control study in China,” Cancer Epidemiology, vol. 35, no. 2, pp. 182–187, 2011.
[14] M. L. Adeoti, A. S. Oguntola, E. O. Akanni, O. S. Agodirin, and G. M. Oyeyemi, “Trace elements; copper, zinc and selenium, in breast cancer afflicted female patients in LAUTECH Osogbo, Nigeria,” Indian Journal of Cancer, vol. 52, no. 1, pp. 106–109, 2015.
[15] M. Sohrabi, A. Gholami, M. H. Azar et al., “Trace element and heavy metal levels in colorectal cancer: comparison between cancerous and non-cancerous tissues,” Biological Trace Element Research, vol. 183, no. 1, pp. 1–8, 2018.
[16] S. S. Khanna and F. R. Karjodkar, “Circulating immune complexes and trace elements (Copper, Iron and Selenium) as markers in oral precancer and cancer: a randomised, controlled clinical trial,” Head & Face Medicine, vol. 2, no. 1, pp. 33, 2006 Published 2006 Oct 16.
[17] A. K. Baltaci, T. K. Dundar, F. Aksoy, and R. Mogulkoc, “Changes in the serum levels of trace elements before and after the operation in thyroid cancer patients,” Biological Trace Element Research, vol. 175, no. 1, pp. 57–64, 2017.
[18] S. Basu, M. K. Singh, T. B. Singh, S. K. Bhartiya, S. P. Singh, and V. K. Shukla, “Heavy and trace metals in carcinoma of the gallbladder,” World Journal of Surgery, vol. 37, no. 11, pp. 2641–2646, 2013.
[19] S. A. K. Saleh, H. M. Adly, A. A. Abdelkhaliq, and A. M. Nassir, “Serum levels of selenium, zinc, copper, manganese, and iron in prostate cancer patients,” Current Urology, vol. 14, no. 1, pp. 44–49, 2020.
[20] T. Tsang, J. M. Posimo, A. A. Gudiel, M. Cicchini, D. M. Feldser, and D. C. Brady, “Copper is an essential regulator of the autophagic kinasesULK1/2 to drive lung adenocarcinoma,” Nature Cell Biology, vol. 22, no. 4, pp. 412–424, 2020.
[21] D. Gunjan, N. N. Shalimar, N. Nadda et al., “Hepatocellular carcinoma: an unusual complication of longstanding Wilson disease,” Journal of Clinical and Experimental Hepatology, vol. 7, no. 2, pp. 152–154, 2017.
[22] E. J. Ge, A. I. Bush, A. Casini et al., “Connecting copper and cancer: from transition metal signalling to metalloplasia,” Nature Reviews Cancer, vol. 22, no. 2, pp. 102–113, 2022.
[23] D. Cen, D. Brayton, B. Shahandezeh, F. L. Meyskens Jr, and P. J. Farmer, “Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells,” Journal of Medicinal Chemistry, vol. 47, no. 27, pp. 6914–6920, 2004.
[24] L. Cui, A. M. Gouw, E. L. LaGory et al., “Mitochondrial copper depletion suppresses triple-negative breast cancer in mice,” Nature Biotechnology, vol. 39, no. 3, pp. 357–367, 2021.
[25] D. Huster, T. D. Purnat, J. L. Burkhead et al., “High copper selectively alters lipid metabolism and cell cycle machinery in the mouse model of Wilson disease,” Journal of Biological Chemistry, vol. 282, no. 11, pp. 8343–8355, 2007.
[26] D. Huster, M. J. Finegold, C. T. Morgan et al., “Consequences of copper accumulation in the livers of the Atp7b-/- (Wilson disease gene) knockout mice,” American Journal Of Pathology, vol. 168, no. 2, pp. 423–434, 2006.
[27] M. Selbach, B. Schwanhäusser, N. Thierfelder, Z. Fang, R. Khanin, and N. Rajewsky, “Widespread changes in protein synthesis induced by microRNAs,” Nature, vol. 455, no. 7209, pp. 58–63, 2008.
L. P. Lim, N. C. Lau, P. Garrett-Engele et al., “Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs,” *Nature*, vol. 433, no. 7027, pp. 769–773, 2005.

C. M. Wong, F. H. C. Tsang, and I. O. L. Ng, “Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications,” *Nature Reviews Gastroenterology & Hepatology*, vol. 15, no. 3, pp. 137–151, 2018.

R. Tibshirani, “The lasso method for variable selection in the Cox model,” *Statistics in Medicine*, vol. 16, no. 4, pp. 385–395, 1997.

M. S. Rooney, S. A. Shukla, C. J. Wu, G. Getz, and N. Hacohen, “Molecular and genetic properties of tumors associated with local immune cytolytic activity,” *Cell*, vol. 160, no. 1-2, pp. 48–61, 2015.

F. F. Hu, C. J. Liu, L. L. Liu, Q. Zhang, and A. Y. Guo, “Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response,” *Briefings in Bioinformatics*, vol. 22, p. 3, 2021.

K. Yoshihara, M. Shahmoradgoli, E. Martinez et al., “Inferring tumour purity and stromal and immune cell admixture from expression data,” *Nature Communications*, vol. 4, no. 1, p. 2612, 2013.

B. A. Carneiro and W. S. El-Deiry, “Targeting apoptosis in cancer therapy,” *Nature Reviews Clinical Oncology*, vol. 17, no. 7, pp. 395–417, 2020.

Q. Wang, Y. Wang, J. Ding et al., “A bioorthogonal system reveals antitumour immune function of pyroptosis,” *Nature*, vol. 579, no. 7799, pp. 421–426, 2020.

M. Seehawer, F. Heinzmann, L. D’Artista et al., “Necroptosis microenvironment directs lineage commitment in liver cancer [published correction appears in *Nature*. 2018 Nov 8: ],” *Nature*, vol. 562, no. 7725, pp. 69–75, 2018.

N. Chan, A. Willis, N. Kornhauser et al., “Correction: influencing the tumor microenvironment: a phase II study of copper depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence and in preclinical models of lung metastases,” *Clinical Cancer Research*, vol. 26, no. 18, p. 5051, 2020.

R. Rupaimoole and F. J. Slack, “MicroRNA therapeutics: towards a new era for the management of cancer and other diseases,” *Nature Reviews Drug Discovery*, vol. 16, no. 3, pp. 203–222, 2017.

T. Jet, G. Gines, Y. Rondelez, and V. Taly, “Advances in multiplexed techniques for the detection and quantification of microRNAs,” *Chemical Society Reviews*, vol. 50, no. 6, pp. 4141–4161, 2021.

K. L. O’Brien and D. K. Finlay, “Immunometabolism and natural killer cell responses,” *Nature Reviews Immunology*, vol. 19, no. 5, pp. 282–290, 2019.

M. Jia, Z. Li, M. Pan, M. Tao, J. Wang, and X. Lu, “LINC-PINT suppresses the aggressiveness of thyroid cancer by down-regulating miR-767-5p to induce TET2 expression,” *Molecular Therapy - Nucleic Acids*, vol. 22, pp. 319–328, 2020.

K. Zhang and L. Guo, “MiR-767 promotes cell proliferation in human melanoma by suppressing CYLD expression,” *Gene*, vol. 641, pp. 272–278, 2018.

F. Wang, X. Wang, J. Li et al., “CircNOL10 suppresses breast cancer progression by sponging miR-767-5p to regulate SOCS2/IKK/STAT signaling,” *Journal of Biomedical Science*, vol. 28, no. 1, p. 4, 2021 Published 2021 Jan 4.

S. Y. Kwak, J. O. Yoo, H. J. An et al., “miR-5003-3p promotes epithelial-mesenchymal transition in breast cancer cells through Snail stabilization and direct targeting of E-cadherin,” *Journal of Molecular Cell Biology*, vol. 8, no. 5, pp. 372–383, 2016.

Z. Chen, J. Wu, W. Huang et al., “Long non-coding RNA RP11-789C1.1 suppresses epithelial to mesenchymal transition in gastric cancer through the RP11-789C1.1/MiR-5003/E-cadherin Axis,” *Cellular Physiology and Biochemistry*, vol. 47, no. 6, pp. 2432–2444, 2018.

W. Hu, C. S. Chan, R. Wu et al., “Negative regulation of tumor suppressor p53 by microRNA miR-504,” *Molecular Cell*, vol. 38, no. 5, pp. 689–699, 2010.

D. R. Budik, S. Bursač, M. Sheffer et al., “Regulatory module involving FGF13, miR-504, and p53 regulates ribosomal biogenesis and supports cancer cell survival,” *Proceedings of the National Academy of Sciences of the USA*, vol. 114, no. 4, pp. E496–E505, 2017.

Z. Wang, Y. Zhao, Y. Wang, and C. Jin, “Circular RNA circHIAT1 inhibits cell growth in hepatocellular carcinoma by regulating miR-3171/PTEN axis,” *Biomedicine & Pharmacotherapy*, vol. 116, Article ID 108932, 2019.

Y. Wei, R. He, Y. Wu et al., “Comprehensive investigation of aberrant microRNA profiling in bladder cancer tissues,” *Tumor Biology*, vol. 37, no. 9, pp. 12555–12569, 2016.